Stay updated on Nivolumab Combinations in Basal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combinations in Basal Cell Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Combinations in Basal Cell Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedA banner announces NIH website transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference0.8%

- Check8 days agoChange DetectedThe study record is displayed with its recruiting status, treatment cohorts, eligibility criteria, study contacts and locations, and outcome measures. The previous 403 error and NIH transition notice are no longer shown.SummaryDifference59%

- Check15 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2, while the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check22 days agoChange DetectedA sitewide NIH banner announces updates to NIH websites and explains that some content may use “Super Intelligence” instead of “Artificial Intelligence.”SummaryDifference1%

- Check29 days agoChange DetectedThe page footer now shows revision v3.7.2 instead of v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Combinations in Basal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combinations in Basal Cell Carcinoma Clinical Trial page.